BUCHANG PHARMA(SH:603858) Zhong Guo Jing Ji Wang·2025-12-30 09:47Core Viewpoint - The stock price of Buchang Pharmaceutical (603858.SH) declined by 3.44% to 15.70 CNY, resulting in a market value loss of approximately 59.06 million CNY due to a lawsuit involving its subsidiary, Shanghai Hepu Medical Technology Co., Ltd. [1] Group 1: Lawsuit Details - Shanghai Hepu has filed a lawsuit against Jiemai (Shanghai) Medical International Trade Co., Ltd. for contract disputes, with the court accepting the case on November 5, 2025 [1] - The lawsuit arises from a distribution agreement where Shanghai Hepu was an authorized distributor for Jiemai, and after the agreement expired, Jiemai coordinated the transfer of inventory to a new distributor [1] - Shanghai Hepu currently holds approximately 550 million CNY in unsold inventory that has not been transferred, leading to the lawsuit for compensation related to interest and legal fees [1] Group 2: Claims and Financial Implications - Shanghai Hepu is requesting a total of approximately 651.89 million CNY in damages, which includes the repurchase of remaining inventory valued at about 556.16 million CNY, a refund of a prepayment of 3.21 million CNY, and interest losses of approximately 91.73 million CNY [2] - The company acknowledges the uncertainty of the lawsuit's outcome and the potential risk of inventory impairment, which could impact current and future profits [2] - Buchang Pharmaceutical will follow accounting standards and disclose relevant information as required based on the situation [2] Group 3: Company Background - Shanghai Hepu Medical Technology Co., Ltd. was established in 2016 and is a member of Buchang Pharmaceutical, primarily engaged in technology promotion and application services [2] - The company has a registered capital of 200 million CNY, with a paid-in capital of 99.95 million CNY [2]